We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+0.81%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$22.8B
AUM Growth
+$1.74M
Cap. Flow
+$81.8M
Cap. Flow %
0.36%
Top 10 Hldgs %
82.65%
Holding
132
New
12
Increased
20
Reduced
6
Closed
10

Top Buys

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$137M
2
PACB icon
Pacific Biosciences
PACB
+$66.5M
3
KOD icon
Kodiak Sciences
KOD
+$50.2M
4
BLUE
bluebird bio
BLUE
+$50.2M
5
TVTX icon
Travere Therapeutics
TVTX
+$34M

Top Sells

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$144M
2
ADCT icon
ADC Therapeutics
ADCT
+$34.5M
3
AMRN
Amarin Corp
AMRN
+$22.6M
4
PTGX icon
Protagonist Therapeutics
PTGX
+$20.4M
5
NVTA
Invitae Corporation
NVTA
+$11M

Sector Composition

Rank Sector Weight
1 Healthcare 97.88%
2 Financials 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EWTX icon
76
Edgewise Therapeutics
EWTX
$4.26B
$8.3M 0.04%
500,000
– –
CABA icon
77
Cabaletta Bio
CABA
$429M
$8.05M 0.04%
662,063
+25,700
+4% +$237K
CBAY
78
DELISTED
Cymabay Therapeutics
CBAY
$7.92M 0.03%
2,170,464
– –
LONA
79
LeonaBio Inc
LONA
$66.4M
$7.56M 0.03%
80,637
– –
GTH
80
DELISTED
Genetron Holdings Limited ADS
GTH
$6.31M 0.03%
151,769
– –
BMEA icon
81
Biomea Fusion
BMEA
$88.9M
$6.28M 0.03%
524,617
+230,500
+78% +$2.93M
AMYT
82
DELISTED
Amryt Pharma plc American Depositary Shares
AMYT
$6.24M 0.03%
+518,380
New +$5.85M
NGM
83
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$6.13M 0.03%
291,801
– –
RVMD icon
84
Revolution Medicines
RVMD
$38.3B
$6.11M 0.03%
222,222
– –
KURA icon
85
Kura Oncology
KURA
$785M
$5.7M 0.03%
+304,158
New +$5.73M
ATYR
86
aTyr Pharma
ATYR
$47.1M
$5.67M 0.02%
+625,000
New +$3.74M
ALEC icon
87
Alector
ALEC
$169M
$5.46M 0.02%
239,228
– –
RLMD icon
88
Relmada Therapeutics
RLMD
$539M
$5.27M 0.02%
200,996
+124,396
+162% +$3.33M
CCXI
89
DELISTED
ChemoCentryx, Inc.
CCXI
$5.15M 0.02%
+301,195
New +$4.69M
TCDA
90
DELISTED
Tricida, Inc. Common Stock
TCDA
$4.81M 0.02%
1,037,432
+308,132
+42% +$1.28M
HRMY icon
91
Harmony Biosciences
HRMY
$2.06B
$4.74M 0.02%
123,600
– –
REPL icon
92
Replimune Group
REPL
$426M
$4.55M 0.02%
153,512
– –
DNLI icon
93
Denali Therapeutics
DNLI
$3.78B
$4.48M 0.02%
88,738
– –
NEXI
94
DELISTED
NexImmune, Inc. Common Stock
NEXI
$4.45M 0.02%
11,765
– –
HOOK
95
DELISTED
HOOKIPA Pharma
HOOK
$4.13M 0.02%
70,048
– –
ITOS
96
DELISTED
iTeos Therapeutics
ITOS
$4.06M 0.02%
150,346
– –
VINC
97
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
$3.9M 0.02%
+12,069
New +$3.52M
XLRN
98
DELISTED
Acceleron Pharma
XLRN
$3.86M 0.02%
22,430
– –
BNR
99
Burning Rock Biotech
BNR
$94M
$3.74M 0.02%
20,913
– –
AKRO
100
DELISTED
Akero Therapeutics
AKRO
$2.65M 0.01%
118,378
– –
2 3
4
5 6

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q3 2021 Portfolio in Review

As of Q3 2021, Baker Bros. Advisors held 132 positions worth $22.8B, up 0.01% from $22.8B the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Baker Bros. Advisors's Q3 2021 filing shows 12 new, 20 increased, 6 reduced and 10 closed positions. Its largest new stake was Surrozen: 166,667 shares worth $17.7M. The largest sale was Apellis Pharmaceuticals, an estimated $144M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier, followed by Financials.

  • Baker Bros. Advisors's largest Q3 2021 buy was Surrozen: 166,667 shares worth $17.7M.
  • Baker Bros. Advisors added most to Ascendis Pharma A/S in Q3 2021, an estimated $137M increase.
  • Baker Bros. Advisors's biggest Q3 2021 reduction was Amarin Corp, cutting an estimated $22.6M.
  • Baker Bros. Advisors fully exited Apellis Pharmaceuticals in Q3 2021, selling an estimated $144M.
  • Baker Bros. Advisors's ten largest holdings make up 83% of its $22.8B portfolio in Q3 2021.
  • Baker Bros. Advisors opened 12 new positions and closed 10 in Q3 2021.
  • Baker Bros. Advisors's portfolio value rose 0.01% quarter-over-quarter to $22.8B.

Based on Baker Bros. Advisors's 13F filing for Q3 2021, filed 15 Nov 2021.